Genetic mutation suppresses inflammatory response—could be basis for novel treatment of rheumatoid arthritis

Research led by York University’s Faculty of Health reveals how a specific mutation in a protein called TRAF1 can shut down an overactive immune response, dramatically reducing inflammation in mice. Lead researcher Ali Abdul-Sater says this discovery could pave the way for a new class of drugs to treat rheumatoid arthritis.

Stem cell transplant clears clinical safety hurdle for treatment of wet age-related macular degeneration

Age-related macular (AMD) degeneration is a leading cause of vision impairment and blindness in the elderly population. In so-called wet AMD, new, abnormal blood vessels grow in the central part of the retina called the macula, which is required for high-acuity central vision, leading to fluid and blood leakage and macular damage or dysfunction. Although wet AMD accounts for a minority of AMD cases, 90% of AMD-related cases of blindness are due to wet AMD.